The crucial role of payload linker innovation in the growth of ADCs
Combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads, ADCs enable targeted delivery of therapeutics to diseased …
Post
-
-
Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML
On 25 March, Merck (MSD) announced the $6.7bn acquisition of Terns Pharmaceuticals via a subsidiary, as part of its strategic …
-
Otsuka agrees to acquire Transcend Therapeutics for $1.22bn
Otsuka Pharmaceutical has signed an agreement to fully acquire Transcend Therapeutics through its subsidiary Otsuka America for a potential consideration …
-
Eli Lilly and Insilico Medicine forge $2.75bn AI-driven R&D pact
Eli Lilly is joining forces with artificial intelligence (AI)-powered biotech, Insilico Medicine, in a drug discovery and development agreement worth …
-
Novo Nordisk receives FDA approval for basal insulin Awiqli
Novo Nordisk has secured the US Food and Drug Administration (FDA) approval for Awiqli (insulin icodec-abae) injection 700 units/mL, a …
-
Novo Nordisk receives FDA approval for basal insulin Awiqli
Novo Nordisk has secured the US Food and Drug Administration (FDA) approval for Awiqli (insulin icodec-abae) injection 700 units/mL, a …
-
Recordati sizes up €10.9bn CVC Capital acquisition offer
Italian pharmaceutical company, Recordati, has confirmed that it’s weighing an acquisition offer from private equity manager, CVC, which is looking …
-
Podcast: European biotech rallies against US and China powerhouses
As Lisbon played host to BIO Europe Spring, an annual conference that brings together professionals across the global biotech sector, …
-
J&J’s Darzalex nets first self-administered cancer injectable approval
Johnson & Johnson’s (J&J) blockbuster cancer immunotherapy, Darzalex (daratumumab), has secured European approval for self-administration, marking the first time an …
-
Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease
The US Food and Drug Administration (FDA) has approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel) in leukocyte adhesion deficiency type I …
-
Novartis to acquire Excellergy for $2bn upfront
Novartis has signed an agreement to acquire biotech business Excellergy, which specialises in the development of next-generation anti-immunoglobulin e (IgE) …
-
Simulations Plus and three pharma companies collaborate on AI-driven drug development
Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled modelling in drug development. The partnerships aim …
-
Corcept’s first-in-class ovarian cancer drug gains FDA approval
Corcept Therapeutics has secured US approval for its selective glucocorticoid receptor agonist, Lifyorli (relacorilant), in ovarian cancer more than three …
-
FDA opens door to feedback on ‘unclear’ national priority voucher pathway
The US Food and Drug Administration (FDA) will convene a public hearing intended to obtain feedback on its Commissioner's National …
-
Cognito Therapeutics and Ochsner partner for new brain health approaches
US-based neurotechnology company Cognito Therapeutics has collaborated with Ochsner Health to establish the Brain Health Collaboratory, aiming to advance new …
